This site is intended for healthcare professionals
News

NMPA (Japan) approval for Yutiq for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye- Eyepoint Pharma + OcuMension Therapeutics.

Read time: 1 mins
Published:26th Jun 2022

EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics a fast-growing ophthalmology focused pharmaceutical company in China, announced that China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has approved Yutiq (fluocinolone acetonide intravitreal implant) 0.18mg for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

 

Yutiq is the first drug approved for commercialization in China based entirely on real-world data, as well as the first drug approved for commercial use in OcuMension’s innovative pipeline .In September 2020, OcuMension launched a real-world study of Yutiq for the treatment of chronic, non-infectious uveitis affecting the posterior segment of the eye at Boao Lecheng Super Hospital in Hainan Province through the urgent clinical need channel granted to Boao Lecheng Pilot Zone. In April 2021, the CDE accepted OcuMension’s new drug application (NDA) for Yutiq that was filed with the real-world data collected at Boao Lecheng Super Hospital.

.

Condition: Uveitis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.